Safety And Effectiveness Study Of CPI-613 And/or Gemcitabine To Treat Metastatic Pancreatic Cancer

Study Overview

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

This Phase II study is conducted to assess the safety and efficacy of CPI-613 in patients with metastatic pancreatic cancer. The primary outcome measure is Overall Survival (OS). The secondary outcome measures are: changes in CA 19-9, Quality of Life (QOL), Progression-Free Survival (PFS), and safety.

Data from dose-escalated Phase I trials indicate that CPI-613 is safe and effective against metastatic pancreatic cancer (Lee et al. 2012; Retter et al. 2012). Accordingly, this Phase II trial is conducted to assess the safety and efficacy of CPI-613 in patients with metastatic pancreatic cancer. Primary Outcome Measure: - Overall Survival (OS) Secondary Outcome Measures: * Changes in CA 19-9 * Quality of Life (QOL) assessment * Progression-Free Survival (PFS) * Safety

Metastatic Pancreatic Adenocarcinoma

DRUG: CPI-613
DRUG: Gemcitabine
DRUG: Any non-gemcitabine chemotherapies or best supportive care

CL-CPI-613-024

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2013-04-03	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2013-08-13
First Submitted that Met QC Criteria 2013-04-09	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ESTIMATED) 2013-08-14
First Posted (ESTIMATED) 2013-04-12	Results First Posted N/A	Last Verified 2013-08

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Non Randomized

Interventional Model:
Parallel

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: CPI-613 Alone This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 i	DRUG: CPI-613 CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of
ACTIVE_COMPARATOR: Any non-gemcitabine chemotherapies or best supportive care This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. This arm includes any best-practice standard-of-care chemotherapies deemed appropriate by the clinical investigators, includ	DRUG: Any non-gemcitabine chemotherapies or best supportive care
EXPERIMENTAL: Gemcitabine + CPI-613 in combination This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. When gemcitabine and CPI-613 are administered in combination, gemcitabine will be administered via 30-minute intravenous (IV) in	DRUG: CPI-613 CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of DRUG: Gemcitabine
EXPERIMENTAL: Gemcitabine alone or in combination with therapeutic agent(s) This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. Gemcitabine, or Gemcitabine-based, chemotherapy will be administered via 30-minute intravenous (IV) infusion at a concentration	DRUG: Gemcitabine

Primary Outcome Measures	Measure Description	Time Frame
Overall Survival (OS)		Monitored until participants pass away, for an expected average of 6 months.

Secondary Outcome Measures	Measure Description	Time Frame
Changes in CA 19-9	CA 19-9 is monitored through blood work ≤2 weeks before treatment and after every third cycle (12 weeks) of treatment while on-study. CA 19-9 is a pancreatic tumor biomarker and a decline in CA 19-9 during and after therapy may be a marker of treatment efficacy.	Monitored within 2-weeks before treatment, and every 3-cycles (months) during treatment
Quality of Life (QOL)	QOL will be assessed as described by Aaronson NK, et al. 1993. It assesses how the various treatments and the disease affect the daily living abilities of the patient.	Monitored before, during, and 1-week after treatment with CPI-613, for an expected average of 20 weeks.
Progression-Free Survival (PFS)		Monitored during treatment with CPI-613 and until participants passed away, which will be an expected average of 6 months.
Safety	Safety assessment will be based on clinical signs, vital signs, blood work, adverse events (AEs), serious adverse events (SAEs), etc.	Monitored just before study treatment, and during study treatment at the end of every 4-week treatment cycle, for an expected average of 20 weeks.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Histologically and cytologically confirmed, measurable metastatic pancreatic adenocarcinoma
Eastern Cooperative Oncology Group (ECOG) performance status being 0-2
Expected survival >2 months
18 years of age or older of both genders
Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation. (Note: Pregnant patients are excluded because the effects of CPI-613 on a fetus are unknown.)
Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists.
At least 2 weeks must have elapsed from any prior surgery or hormonal therapy. Must have fully recovered from the acute toxicities of any prior treatment with any anti-cancer drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment). Patients with persisting, stable chronic toxicities from prior treatment ≤Grade 1 are eligible, but must be documented as such.
Laboratory values ≤2 weeks must be:

Adequate hematologic (white blood cell [WBC] ≥3500 cells/mm3 or ≥3.5 bil/L; platelet count ≥150,000 cells/mm3 or ≥150 bil/L; absolute neutrophil count [ANC] ≥1500 cells/mm3 or ≥1.5 bil/L; and hemoglobin (Hgb) ≥9 g/dL or ≥90 g/L).
Adequate hepatic function (aspartate aminotransferase [AST/SGOT] ≤3x upper normal limit [UNL], alanine aminotransferase [ALT/SGPT] ≤3x UNL (≤5x UNL if liver metastases present), bilirubin ≤1.5x UNL).
Adequate renal function (serum creatinine ≤2.0 mg/dL or 177 μmol/L, and blood urea nitrogen [BUN] ≤25 mg/dL).
Adequate coagulation ("International Normalized Ratio or INR must be <1.5"), unless treated with anticoagulants.
No evidence of active infection and no serious infection within the past month; no systemic fungal, bacterial, viral or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment.
Consent to participating the study by signed informed consent form

Serious medical illness that would potentially increase patients' risk for toxicity
Any active uncontrolled bleeding or patients with a bleeding diathesis (e.g., active peptic ulcer disease)
Patients with active central nervous system (CNS) or epidural tumor
Lactating females (Note: Lactating females are excluded because the effects of CPI-613 on a nursing child are unknown)
Life expectancy less than 2 months
Unwilling or unable to follow protocol requirements
Dyspnea with minimal to moderate exertion, or patients with pleural, pericardial, or peritoneal effusions
Active heart disease including but not limited to symptomatic congestive heart failure, symptomatic coronary artery disease, symptomatic angina pectoris, symptomatic myocardial infarction, arrhythmias requiring medication, or symptomatic congestive heart failure. Also patients with a history of myocardial infarction that is <1 year prior to registration, or patients with previous congestive heart failure (<1 year prior to registration) requiring pharmacologic support or with Left Ventricular Ejection Fraction <50%).
A marked baseline prolongation of QT/QTc interval (e.g., repeated exhibition of a QTc interval >470 ms.); a history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
Requirement for immediate palliative treatment of any kind including surgery
Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

STUDY_CHAIR: King C Lee, Ph.D., Cornerstone Pharmaceuticals

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record